Please assess the completion status of the following clinical trial:

Trial Title: Pilot Randomized Trial With Flecainide in ARVC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Subjects who have been diagnosed with ARVC and meet 2010 Modified Task Force Criteria for ARVC as affected.~* At minimum 500 VEBs on the most recent 24-hour Holter monitor recording prior to consent or after consent if a subsequent recording is required after 5 day washout following discontinuation of anti-arrhythmic medication.~* Functioning implanted cardioverter defibrillator with remote interrogation capability.~* Subjects should be on a beta-blocker including metoprolol, propranolol, atenolol, nadolol, carvedilol or bisoprolol unless contraindication to beta-blockers exists.~* Persons prescribed quinidine, procainamide, propafenone, disopyramide, dronedarone phenytoin, mexiletene, flecainide, may be included after 5 day washout period with subsequent 24 Hour Holter obtained after washout period.~* Persons prescribed sotalol must be included after 5 day washout period during which another beta-blocker may be administered with subsequent 24 Hour Holter obtained.~* Subject and personal physician and or cardiologist must agree not to use any antiarrhythmic medications during the 10 weeks of participation, unless needed for management of life-threatening arrhythmias.~* All subjects must agree to use medically acceptable contraceptive measures during participation unless documented as surgically sterile or post-menopausal (no menstrual periods for more than one year).~Exclusion Criteria:~* Prescribed amiodarone or dofetilide at the time of consent.~* Left ventricular ejection fraction ≤40% by any imaging modality: echocardiography, angiography, cardiac magnetic resonance imaging (CMRI), or cardiac nuclear test on the most recent test.~* New York Heart Association (NYHA) heart failure class III or IV at time of consent.~* Prior myocardial infarction at any time in the past.~* Pacemaker dependent rhythm at the time of consent.~* Renal impairment (GFR \<30 mL/min/m2).~* Prior diagnosis of severe hepatic impairment.~* Pregnant or plan to become pregnant during the course of the trial (Flecainide has not been adequately studied in pregnant women). Pregnancy test is required for women of child-bearing potential prior to randomization.~* Participating in any other interventional clinical trial.~* Unwilling or unable to cooperate with the protocol.~* Lives at such a distance from the clinic that travel for the consent visit would be unusually difficult.~* Decisionally impaired adults, those of questionable capacity, those who cannot manage taking the study drug per the prescribed regimen, and those who cannot consent for themselves will not be recruited for this study.~* Unwilling to sign the consent for participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flecainide (Type: ACTIVE_COMPARATOR): The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
- Placebo (Type: PLACEBO_COMPARATOR): The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete